
News
Home>News & Events>Publications>CPP>The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
104
Related Posts
-
Effective Data Sharing as a Conduit for Advancing Medical Product Development
-
Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science
-
Remote Digital Monitoring for Medical Product Development
-
Development of a disease progression model for leucine-rich repeat kinase 2 in Parkinson’s disease to inform clinical trial designs
-
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease